Sensible use of antisense: How to use oligonucleotides as research tools

Trends in Pharmacological Sciences

Volumn 21, Issue 1, 2000, Pages 19-23

  Myers, Kathleen J ^a   Dean, Nicholas M ^a  

^a ISIS PHARMACEUTICALS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; MESSENGER RNA; PHOSPHOROTHIOIC ACID DERIVATIVE; RIBONUCLEASE H;

CLINICAL TRIAL; COMPUTER PROGRAM; CYTOMEGALOVIRUS INFECTION; DRUG DESIGN; DRUG RESEARCH; GENE TARGETING; GENETIC TRANSFECTION; HUMAN; IN VITRO STUDY; IN VIVO STUDY; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RETINITIS; REVIEW; RNA CLEAVAGE; RNA SEQUENCE; RNA SPLICING; RNA TRANSLATION;

ANIMALS; HUMANS; OLIGONUCLEOTIDES, ANTISENSE; RNA, MESSENGER;

EID: 0033975328     PISSN: 01656147     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0165-6147(99)01420-0     Document Type: Review

References (54)

1. Cossum P.A.et al. Disposition of the 14C-labeled phosphorothioate oligonucleotide ISIS 2105 after intravenous administration to rats. J. Pharmacol. Exp. Ther. 267:1993;1181-1190.
2. Agrawal S.et al. Pharmacokinetics, biodistribution, and stability of oligodeoxynucleotide phosphorothioates in mice. Proc. Natl. Acad. Sci. U. S. A. 88:1991;7595-7599.
3. Eder P.S.et al. Substrate specificity and kinetics of degradation of antisense oligonucleotides by a 3′ exonuclease in plasma. Antisense Res. Dev. 1:1991;141-151.
4. Walder R.Y., Walder J.A. Role of RNase H in hybrid-arrested translation by antisense oligonucleotides. Proc. Natl. Acad. Sci. U. S. A. 85:1988;5011-5015.
5. Dash P.et al. Selective elimination of mRNAs in vivo: Complementary oligodeoxynucleotides promote RNA degradation by an RNase H-like activity. Proc. Natl. Acad. Sci. U. S. A. 84:1987;7896-7900.
6. Kanaya S., Ikehara M. Functions and structures of ribonuclease H enzymes. Subcell. Biochem. 24:1995;377-422.
7. Altmann K.-H.et al. Second generation of antisense oligonucleotides. From nuclease resistance to biological efficacy in animals. Chimia. 50:1996;168-176.
8. Dean N.M., Griffey R.H. Identification and characterization of second-generation antisense oligonucleotides. Antisense Nucleic Acid Drug Dev. 7:1997;229-233.
9. Cook, P.D. (1998) Antisense medicinal chemistry. In Antisense Research and Application (Vol. 131) (Crooke, S.T., ed.), pp. 51-101, Springer-Verlag.
10. Freier S.M., Altmann K.-H. The ups and downs of nucleic acid duplex stability: structure-stability studies on chemically-modified DNA:RNA duplexes. Nucleic Acids Res. 25:1997;4429-4443.
11. Agrawal S. Antisense oligonucleotides: towards clinical trials. Trends Biotechnol. 14:1996;376-387.
12. Crooke, S.T. (1998) Basic principles of antisense therapeutics. In Antisense Research and Application (Vol. 131) (Crooke, S.T., ed.), pp. 1-50, Springer-Verlag.
13. Stein C.A., Cheng Y.-C. Antisense oligonucleotides as therapeutic agents- Is the bullet really magical? Science. 261:1993;1004-1012.
14. Thierry A.R., Dritschilo A. Intracellular availability of unmodified, phosphorothioated and liposomally encapsulated oligodeoxynucleotides for antisense activity. Nucleic Acids Res. 20:1992;5691-5698.
15. Campbell J.M.et al. Oligodeoxynucleoside phosphorothioate stability in subcellular extracts, culture media, sera and cerebrospinal fluid. J. Biochem. Biophys. Meth. 20:1990;259-267.
16. Akhtar S.et al. Stability of antisense DNA oligodeoxynucleotide analogs in cellular extracts and sera. Life Sci. 49:1991;1793-1801.
17. McKay R.A.et al. Characterization of a potent and specific class of antisense oligonucleotide inhibitor of human protein kinase C-a expression. J. Biol. Chem. 274:1999;1715-1722.
18. Branch A.D. A good antisense molecule is hard to find. Trends Biochem. Sci. 23:1998;45-50.
19. Monia B.P.et al. Selective inhibition of mutant Ha-ras mRNA expression by antisense oligonucleotides. J. Biol. Chem. 267:1992;19954-19962.
20. Dean N.M.K.et al. The use of antisense oligonucleotides to inhibit expression of isoenzymes of protein kinase C. Applied Antisense Oligonucleotide Technology. 1998;193-205 Wiley-Liss.
21. Wyatt J.R.et al. Kinetics of G-quartet-mediated tetramer formation. Biochemistry. 35:1996;8002-8008.
22. Ecker D.J.et al. Novel guanosine quartet structure binds to the HIV envelope and inhibits envelope mediated cell fusion. Nucleosides Nucleotides. 14:1995;1117-1127.
23. Yamamoto S.et al. Unique palindromic sequences in synthetic oligonucleotides are required to induce IFN and augment IFN-mediated natural killer activity. J. Immunol. 148:1992;4072-4076.
24. Monteith D.K.et al. Immune stimulation- a class effect of phosphorothioate oligodeoxynucleotides in rodents. Anti-Cancer Drug Des. 12:1997;421-432.
25. Krieg A.M.et al. CpG motifs in bacterial DNA trigger direct B-cell activation. Nature. 374:1995;546-549.
26. Stull R.A.et al. Predicting antisense oligonucleotide inhibitory efficacy: a computational approach using histograms and thermodynamic indices. Nucleic Acids Res. 20:1992;3501-3508.
27. Ho S.P.et al. Potent antisense oligonucleotides to the human multidrug resistance-1 mRNA are rationally selected by mapping RNA-accessible sites with oligonucleotide libraries. Nucleic Acids Res. 24:1996;1901-1907.
28. Milner N.et al. Selecting effective antisense reagents on combinatorial oligonucleotide arrays. Nat. Biotechnol. 15:1997;537-541.
29. Tu G.C.et al. Tetranucleotide GGGA motif in primary RNA transcripts. Novel target site for antisense design. J. Biol. Chem. 273:1998;25125-25131.
30. Bennett C.F.et al. Cationic lipids enhance cellular uptake and activity of phosphorothioate antisense oligonucleotides. Mol. Pharmacol. 41:1992;1023-1033.
31. Gewirtz A.M.et al. Facilitating oligonucleotide delivery: Helping antisense deliver on its promise. Proc. Natl. Acad. Sci. U. S. A. 93:1996;3161-3163.
32. Bennett C.F. Intracellular delivery of oligonucleotides with cationic liposomes. Akhtar S. Delivery Strategies for Antisense Oligonucleotide Therapeutics. 1995;223-232 CRC Press.
33. Bongartz J.-P.et al. Improved biological activity of antisense oligonucleotides conjugated to a fusogenic peptide. Nucleic Acids Res. 22:1994;4681-4688.
34. Kukowaska-Latallo J.F.et al. Efficient transfer of genetic material into mammalian cells using Starbust polyamidoamine dendrimers. Proc. Natl. Acad. Sci. U. S. A. 93:1996;4897-4902.
35. Boussif O.et al. A versatile vector for gene and oligonucleotide transfer into cells in culture and in vivo: Polyethylenimine. Proc. Natl. Acad. Sci. U. S. A. 92:1995;7297-7301.
36. Bergan R.et al. Electroporation enhances c-myc antisense oligodeoxynucleotide efficacy. Nucleic Acids Res. 21:1993;3567-3573.
37. Giles R.V.et al. Selecting optimal oligonucleotide composition for maximal antisense effect following streptolysin O-mediated delivery into human leukaemia cells. Nucleic Acids Res. 26:1998;1567-1575.
38. Zelphati O., Szoka F.C. Jr. Mechanism of oligonucleotide release from cationic liposomes. Proc. Natl. Acad. Sci. U. S. A. 93:1996;11493-11498.
39. Marcusson E.G.et al. Phosphorothioate oligodeoxyribonucleotides dissociate from cationic lipids before entering the nucleus. Nucleic Acids Res. 26:1998;2016-2023.
40. Vaerman J.L.et al. Antisense oligodeoxyribonucleotides suppress hematologic cell growth through stepwise release of deoxyribonucleotides. Blood. 90:1997;331-339.
41. Yakubov L.et al. Oligodeoxynucleotides interact with recombinant CD4 at multiple sites. J. Biol. Chem. 268:1993;18818-18823.
42. Perez J.R.et al. Sequence-independent induction of Sp1 transcription factor activity by phosphorothioate oligodeoxynucleotides. Proc. Natl. Acad. Sci. U. S. A. 91:1994;5957-5961.
43. Guvakova M.A.et al. Phosphorothioate oligodeoxynucleotides bind to basic fibroblast growth factor, inhibit its binding to cell surface receptors, and remove it from low affinity binding sites on extracellular matrix. J. Biol. Chem. 270:1995;2620-2627.
44. 3H-labeled oligonucleotides. I. Comparison of a phosphodiester and a phosphorothioate. Mol. Pharmacol. 45:1994;932-943.
45. Dean N.M., McKay R. Inhibition of protein kinase C-α expression in mice after systemic administration of phosphorothioate antisense oligodeoxynucleotides. Proc. Natl. Acad. Sci. U. S. A. 91:1994;11762-11766.
46. Butler M.et al. Histological localization of phosphorothioate oligodeoxynucleotides in normal rodent tissue. Lab. Invest. 77:1997;379-388.
47. Galbraith W.M.et al. Complement activation and hemodynamic changes following intravenous administration of phosphorothioate oligonucleotides in the monkey. Antisense Res. Dev. 4:1994;201-206.
48. Henry S.P.et al. Evaluation of the toxicity profile of ISIS 2302, a phosphorothioate oligonucleotide in a 4-week study in CD-1 mice. Antisense Nucleic Acid Drug Dev. 7:1997;473-481.
49. Pisetsky D.S., Reich C.F. Stimulation of murine lymphocyte proliferation by a phosphorothioate oligonucleotide with antisense activity for herpes simplex virus. Life Sci. 54:1994;101-107.
50. Monia, B.P. and Dean, N.M. (1998) Pharmacological activity of antisense oligonucleotides in animal models of disease. In Antisense Research and Application (Vol. 131) (Crooke, S.T., ed.), pp. 428-443, Springer-Verlag.
51. Bennett, C. F. et al. (1996). Pharmacology of antisense therapeutic agents, pp. 13-46, Humana.
52. Dean N.et al. Inhibition of growth of human tumor cell lines in nude mice by an antisense oligonucleotide inhibitor of protein kinase C-α expression. Cancer Res. 56:1996;3499-3507.
53. Monia B.P.et al. Antitumor activity of a phosphorothioate antisense oligodeoxynucleotide targeted against C-raf kinase. Nat. Med. 2:1996;668-675.
54. Anderson K.P.et al. Inhibition of human cytomegalovirus immediate-early gene expression by an antisense oligonucleotide complementary to immediate-early RNA. Antimicrob. Agents Chemother. 40:1996;2004-2011.